ZCMD - Zhonachao Reports Renewal of Partnership with China Association of Health Promotion and Education and GlaxoSmithKline

Zhongchao Inc. (NASDAQ: ZCMD) reported renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program “Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals” in 2021.  The PAH Project aims to promote the implementation of multidisciplinary treatment model of pulmonary hypertension and improve doctors’ ability to solve clinical problems.

Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, “Compared to the population base and the number of potential pulmonary hypertension patients in China, the number of physicians specializing in the diagnosis and treatment of this field is very limited. Therefore, our PAH project in 2020 had received positive response and recognition from the majority of clinicians. The success of the PAH project brings valuable experiences for us in educating rare diseases. We believe we will attract more social and commercial cooperation in promoting rare diseases education to grow our business further.”

The post Zhonachao Reports Renewal of Partnership with China Association of Health Promotion and Education and GlaxoSmithKline first appeared on Financial Buzz .

For further details see: